BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01925599
Recruitment Status : Unknown
Verified August 2016 by Amy C Schefler, MD, Greater Houston Retina Research. Recruitment status was: Recruiting
First Posted : August 20, 2013
Last Update Posted : August 8, 2016
Amy C Schefler, MD
Information provided by (Responsible Party):
Amy C Schefler, MD, Greater Houston Retina Research
The BAP1 trial will examine the blood of patients diagnosed with choroidal nevi or uveal melanoma for a germline BAP1 mutation and other genetic markers associated with developing malignancy as well as additional sequencing of the uveal melanoma genome.
Condition or disease
Choroidal Nevi, Uveal Melanoma
A germline BAP1 mutation predisposes a person to developing uveal melanoma and other cancers. If a mutation is discovered, it changes the potential approach to managing the nevus. In the presence of a known genomic change associated with aggressive disease, closer follow up and more aggressive treatment could preserve the patient's vision and prevent micrometastatic spread. This new screening technique will be able to extend the length and quality of life of patients with more frequent targeted cancer screens.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients age > 18 years, diagnosed with choroidal nevi or uveal melanoma
any person with choroidal nevi
Willingness to provide signed informed consent
Age > 18 years
Diagnosis of choroidal nevi or uveal melanoma
Threre are no exclusionary criteria for this study.